Please assess the completion status of the following clinical trial:

Trial Title: Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Man or woman aged 18 years or older~* Patient diagnosed with a visual impairment due to diabetic macular disease (as defined by HAS (Haute Autorité de Santé) recommendation).~* Patients in whom a decision to treat with intravitreal aflibercept has been made independently of the patient enrollment in the study~* Patient diagnosed with type 1 or 2 diabetes mellitus~* Patient who has been given appropriate information about the study and who has given his/her written, informed consent~Exclusion Criteria:~* Patient with other retinal disease at the time of inclusion~* Patients currently being treated with intravitreal aflibercept. This study will only include patients new to intravitreal aflibercept~* Systemic use of any anti / pro VEGF therapy (VEGF: Vascular Endothelial Growth Factor)~* Patient taking part in an interventional study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Previously treated patient (Type: None): Already treated with any other treatment such as an anti-VEGF agent (other than IVT aflibercept), macular laser photocoagulation (laser), intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
- Naïve patient (Type: None): Not previously treated with an anti-VEGF agent, macular laser photocoagulation (laser) or intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
- Entire study population (Type: None): Already treated patient with any other treatment such as an anti-VEGF agent (other than intravitreal aflibercept), macular laser photocoagulation, intravitreal steroid injection and initiating treatment with intravitreal aflibercept and not previously treated patients with an anti-VEGF agent, macular laser photocoagulation or intravitreal steroids injection and initiating treatment with intravitreal aflibercept

Based on this trial design, predict the completion outcome and termination type (if applicable).